Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3141 (miR-3141, also known as hsa-mir-3141 or MIR3141) is a short, non-coding RNA molecule classified as a microRNA[1]. MicroRNAs are typically 20–24 nucleotides in length and are generated through a multi-step biogenesis process involving RNA polymerase II transcription, processing by Drosha and Dicer nucleases, and assembly into the RNA-induced silencing complex (RISC)[1][3]. Mature microRNAs guide RISC to recognize complementary sequences in target mRNAs, resulting in inhibition of translation or mRNA degradation and thus post-transcriptional regulation of gene expression[1][3]. MicroRNA 3141 is reported in databases (GeneCards, HGNC), but there are no specific studies confirming it as a validated therapeutic target, nor any known interactions with drugs, specific disease mechanisms, or established biomarker roles[1]. It has been associated in some sources with thrombocytopenia by database linkage, but literature confirming this functional or clinical association is lacking[1]. Additional notes: - MIR3141 is not a receptor, enzyme, transporter, or protein; it is a non-coding RNA, so it does not fit classic drug target categories[1][3]. - There are no published studies specifically detailing its biological activity, targets, involvement in signaling pathways, or disease mechanisms beyond database annotations. - No drugs, mechanism-of-action, biomarker, or safety information specific to MIR3141 is available. - The gene and mature miRNA are referenced in gene and RNA databases (GeneCards, HGNC, NCBI, miRBase), lending support that this is a correctly annotated microRNA, but its functional characterization remains absent in the scientific literature[1]. Given this, MIR3141 is a cataloged but poorly characterized microRNA, currently not considered a therapeutic target, and very little structured biological or clinical data exists for it. If your interest is in discovering experimentally validated microRNA targets for therapy or biomarkers, more established microRNAs should be considered. [1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3141 (miR-3141).